Você procurou por: interleukiin (Estoniano - Inglês)

interleukiin-2 (il-2)
interleukin-2 (il-2)

interleukiin-2 (vähi raviks)
interleukin-2 (to treat cancer)

interleukiin-2 (kasvajate raviks),
interleukin-2 (to treat cancer).

interleukiin-2 (il-2, aldesleukiin)
interleukin-2 (il-2, aldesleukin)

kasside interleukiin-2 rekombinantne kanaarilinnurõugete viirus
feline interleukin-2 recombinant canary pox virus

ceplenet ja interleukiin-2 manustatakse 10 ravikuurina.
ceplene and interleukin-2 are given for 10 cycles.

kui ceplenet manustatakse koos interleukiin- 2- ga, aitab
this improves the effectiveness of interleukin-2, a medicine that stimulates the immune system to attack cancerous cells.

see blokeerib organismi keemilise virgatsaine interleukiin-1 retseptoreid.
it blocks the receptors for a chemical messenger in the body called interleukin 1.

muud ravimid, mis blokeerivad interleukiin 1, nagu anakinra või kanakinumab.
other medicines that block interleukin-1, such as anakinra or canakinumab.

interleukiin-2 (vähi raviks), adefoviirdipivoksiil (hbv raviks),
interleukin-2 (to treat cancer), adefovir dipivoxil (for hbv),

kanakinumaab seondub organismis leiduva virgatsaine tsütokiini interleukiin-1β retseptoriga.
canakinumab has been designed to attach to a messenger molecule or ‘cytokine’ in the body called interleukin-1 beta.

cd25 on t-lümfotsüütide jagunemist stimuleeriva virgatsaine interleukiin-2 retseptor.
cd25 is a receptor for the messenger interleukin-2, which stimulates the t-lymphocytes to divide.

reumatoidartriidi korral toodab teie keha liiga palju tsütokiini nimetusega interleukiin-1.
in rheumatoid arthritis, your body produces too much of a cytokine called interleukin-1.

daklitsumab seondub valgeliblede t- lümfotsüütide pinnal leiduvate interleukiin-2 retseptoritega.
daclizumab has been designed to bind to the receptor for interleukin-2 on the surface of white blood cells called t-lymphocytes.

ceplenet manustati koos interleukiin-2-ga ja võrreldi selle toimet ravi puudumisega.
ceplene was given in combination with interleukin-2 and compared with no treatment.

cd25-ga seondudes blokeerib basiliksimab interleukiin-2 toime, aeglustades lümfotsüütide paljunemist.
by binding to cd25, basiliximab blocks the activity of interleukin-2, reducing the rate at which the

esimesel nädalal pärast neeru siirdamist tuleb koos nulojixiga kasutada ka interleukiin-2 retseptori antagonisti.
an interleukin-2 receptor antagonist medicine should also be used with nulojix during the first week after the kidney transplant.

kinereti toimeaine anakinra on inimese loodusliku valgu, inimese interleukiin-1 retseptori antagonisti analoog.
the active substance in kineret, anakinra, is a copy of a natural human protein called ‘human interleukin 1 receptor antagonist’.

interleukiin-17a-ga seondudes blokeerib sekukinumab selle toime ning vähendab nii immuunsüsteemi aktiivsust ja haigussümptomeid.
by attaching to and blocking the action of interleukin 17a, secukinumab reduces the activity of the immune system and the symptoms of the disease.

see suurendab interleukiin-2 (ravim, mis stimuleerib immuunsüsteemi rakke vähirakke ründama) tõhusust.
this improves the effectiveness of interleukin-2, a medicine that stimulates the immune system to attack cancerous cells.